Bicnu en es it fr

Bicnu Brand names, Bicnu Analogs

Bicnu Brand Names Mixture

  • No information avaliable

Bicnu Chemical_Formula


Bicnu RX_link

Bicnu fda sheet

Bicnu msds (material safety sheet)

Bicnu MSDS

Bicnu Synthesis Reference

Johnston TP et al. J Med Chem 122:669-681(1963).

Bicnu Molecular Weight

214.049 g/mol

Bicnu Melting Point

31 oC

Bicnu H2O Solubility

< 0.1 g/100 mL at 18 °C

Bicnu State


Bicnu LogP


Bicnu Dosage Forms

Powder for solution; Wafer

Bicnu Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Bicnu Pharmacology

Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.

Bicnu Absorption

5 to 28% bioavailability

Bicnu side effects and Toxicity

The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.

Bicnu Patient Information

No information avaliable

Bicnu Organisms Affected

Humans and other mammals